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Abstract HERG (human ether-à-go-go-related gene) K
+
currents fulfill important ionic functions in cardiac and
other excitable cells. In addition, HERG channels influence
cell growth and migration in various types of tumor cells.
The mechanisms underlying these functions are still not
resolved. Here, we investigated the role of HERG channels
for cell growth in a cell line (SW2) derived from small cell
lung cancer (SCLC), a malignant variant of lung cancer.
The two HERG1 isoforms (HERG1a, HERG1b) as well as
HERG2 and HERG3 are expressed in SW2 cells. Inhibition
of HERG currents by acute or sustained application of E-
4031, a specific ERG channel blocker, depolarized SW2
cells by 10–15 mV. This result indicated that HERG K
+
conductance contributes considerably to the maintenance of
the resting potential of about −45 mV. Blockage of HERG
channels by E-4031 for up to 72 h did not affect cell
proliferation. In contrast, siRNA-induced inhibition of
HERG1 protein expression decreased cell proliferation by
about 50%. Reduction of HERG1 protein expression was
confirmed by Western blots. HERG current was almost
absent in SW2 cells transfected with siRNA against
HERG1. Qualitatively similar results were obtained in three
other SCLC cell lines (OH1, OH3, H82), suggesting that
the HERG1 channel protein is involved in SCLC cell
growth, whereas the ion-conducting function of HERG1
seems not to be important for cell growth.
Keywords HERG.Small cell lung cancer.Cell
proliferation.Oncogenic potential.Protein expression.
Membrane currents
Introduction
Small cell lung cancer (SCLC) derived from a primitive
neuroectodermal stem cell is one of the most aggressive forms
of cancer, with a median survival time from diagnosis of only
months [23]. The poor prognosis of SCLC patients is due to
the fact that SCLC metastasizes early and develops resistance
towards chemo- and radiotherapy rapidly. This unfavorable
prognosis stimulated the search for molecular mechanisms
involved in SCLC initiation, progression, and treatment.
K
+ channels are involved in the generation of the resting
potential and repolarization of the action potential [10]. In
addition to these ion-conducting functions, some types of K
+
channels have additional cellular functions by influencing
cell proliferation and migration. Voltage-dependent Kv1.3
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immune response of lymphocytes comprising cell prolifera-
tion and differentiation [13, 15]. In some tumors, Kv
channels are overexpressed as compared with the normal
tissue and augment uncontrolled cell proliferation and
metastasis, like in breast [11] and prostate [42]c a n c e rc e l l s .
In a number of tumors, it had been demonstrated that
pharmacological blockage of K
+ currents inhibits cell
proliferation. Despite intense research, little is known about
the role which K
+ channels are playing in the molecular
mechanisms underlying malignant transformation from
controlled physiological to uncontrolled pathological cell
growth, and little is known about the mechanisms leading to
inhibition of cell growth by the pharmacological blockage of
K
+ channels [3].
Within the large group of K
+ channels, ether-à-go-go
(EAG) K
+ channels are known for their oncogenic potential
[30, 55]. The EAG ion channel family consists of three
subfamilies: EAG (ether-à-go-go; Kv10), ERG (EAG-related
gene; Kv11), and ELK (EAG-like; Kv12) [8]. Attempts to
clone the human EAG channel led to the detection of the
human ERG (HERG) channel [50]. In the heart, the rapidly
activating component of the delayed rectifying K
+ current
(IKr) is mediated by HERG1 [32]. Blockage of IKr induces a
prolongation of the heart action potential thereby increasing
the risk of the occurrence of life-threatening arrhythmias
(LQT2) [37]. In neurons, neuroendocrine and smooth muscle
cells, HERG channels mediate subthreshold currents, since
they activate near the resting potential and therefore
modulate cell excitability [17, 19, 36].
Pharmacological blockage of HERG channels with selec-
tive blockers significantly reduces cell proliferation in primary
leukemia cells [31], colon cancer cell lines [24], and other
tumors [5, 40]. In the human neuroblastoma cell line SH-
SY5Y [57] and melanoma cells [1], not only pharmacological
ERG channel blockage but also inhibition of HERG channel
protein expression effectively reduces cell proliferation. In the
present work, we show that cell proliferation of SCLC cells is
reduced by siRNA-induced inhibition of HERG1 channel
protein expression, whereas blockage of HERG current by E-
4031 does not influence cell growth. This unexpected result
indicates that, in contrast to many other malignancies, in
SCLC cells, the HERG channel protein itself is connected to
cell proliferation by an intracellular pathway which is
independent from ion flux through the HERG channel.
Methods
SCLC cell lines
SCLC cell lines (SW2, OH1, OH3, H82; kindly provided
by Prof. Dr. U. Zangemeister-Wittke, University of Bern)
were cultured in RPMI-1640 medium supplemented with
10% heat-inactivated fetal calf serum, 2 mML-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco
Invitrogen, Carlsbad, USA) and maintained in a humidified
atmosphere of 5% CO2 in air at 37°C. For electrophysio-
logical recordings, cells were plated in 35 mm plastic
culture dishes (Nunc) coated with poly-D-lysine (Sigma).
Cell proliferation assay
Cells of SCLC cell lines were incubated with a combined
solution of the tetrazolium compound sodium 3′-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-
nitro) benzene sulfonic acid hydrate (XTT) and the electron
coupling reagent PMS (N-methyl dibenzopyrazine methyl
sulfate) (Roche, Mannheim, Germany). The quantity of
formazan formed by reduction of the XTT reagent by viable
proliferating cells was determined. The absorbance of
formazan at 490 nm was directly proportional to the
proliferation rate in the culture (Roche). To investigate the
effect of E-4031 on cell proliferation, samples of SCLC cells
were seeded at a density of 160,000 cells/ml into 96-well
culture plates (Sarstedt) and incubated with 1 or 5 μME -
4031 for 24 to 72 h. Stocks of E-4031 were prepared in
distilled water. Each concentration was tested in triplicate,
and each experiment was repeated independently two or
three times. Data are presented as means ± SEM. The
statistically significant change in cell proliferation was tested
by using the t-test with a Bonferroni correction.
Electrophysiology
Membrane currents were recorded in the whole-cell
configuration of the patch-clamp technique, using an
EPC9 patch-clamp amplifier and Pulse 8.65 software
(HEKA Elektronik, Lambrecht, Germany). The patch
electrodes were made from 1.5 mm diameter borosilicate
glass capillaries. After filling with intracellular solution, the
pipette resistance was 2–4M Ω. Series resistance errors
were compensated for by at least 70%. All experiments
were carried out at room temperature (21–23°C). HERG K
+
current density was calculated by dividing the leak subtracted
peak tail current amplitude measured at −100 mV by the cell
capacitance as estimated from the compensation of the slow
capacitance component with the patch clamp amplifier. Data
were analyzed with PulseFit (HEKA) and Sigma Plot (SPSS,
Chicago, IL, USA). Data are presented as means±SEM.
Availability curves were fitted with the Boltzmann equation
usingSigmaPlot.Student’stwo-tailedpairedorunpairedt-test
was performed to test for significance (Excel, Microsoft).
The extracellular Ringer’s solution contained (in milli-
molars):140 NaCl,5 KCl, 0.8 MgCl2,1C a C l 2,1 0H E P E S ,5
glucose, pH adjusted to 7.3 with NaOH. The 40 mM K
+
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2M g C l 2, 1 CaCl2, 10 HEPES, 5 glucose, pH adjusted to 7.3
with NaOH. Tetrodotoxin (1 μM; TTX; Biotrend, Cologne,
Germany) was added to the external 40 mM KCl solution.
Pipette solution contained (in millimolars): 140 KCl, 2
MgCl2,1C a C l 2, 2.5 EGTA, 10 HEPES (66 nM free Ca
2+,
calculated using Eqcal, Biosoft), pH adjusted to 7.3 with
KOH. E-4031 was a gift of Eisai (Tokyo, Japan).
RT-PCR of SCLC cells
RNAs were extracted from SCLC cells using RNAzol™ B
(AGS, Heidelberg, Germany). DNase digestion was per-
formed routinely before preparing cDNA. Reverse tran-
scription and RT-PCRs with 40 cycles of amplification were
performed as previously described [56]. Amplified DNA
fragments were analyzed by agarose gel electrophoresis. All
RT-PCRs were performed at least two times, and all DNA
fragments were verified by sequencing. In negative con-
trols, H2O was used instead of cDNA as template.
For the PCR amplifications, the following oligonucleo-
tide primer sequences were used (accession no. of the
GenBank database is given in parentheses):
HERG1, nucleotides 1398–1950 (accession no. U04270);
forward 5′CTTCAAGGCCGTGTGGGACT3′; reverse 5′
CAGGTTGTGCAGCCAGCCGA3′
HERG1a, nucleotides 173–603 (accession no. U04270);
forward 5′ATGGGCTCAGGATGCCGGTG3′; reverse
5′GGACCCCACCATGTCCTTCT3′
HERG1b, nucleotides 327–1073 (accession no.
NM_172057); forward 5′ATGGCGGCCCCAGCCGG
GAA3′; reverse 5′CAGGTTGTGCAGCCAGCCGA3′
HERG2, nucleotides 2507–2993 (accession no.
AF311913); forward 5′GATGAACAGGCTG
GAGTCCC3′; reverse 5′GTGGCCCCAACTCCCTG
CAA3′
HERG3, nucleotides 2114–2670 (accession no.
AF032897); forward 5′GGAACTGCCAGGTACCA
CAT3′; reverse 5′GTTAGAAAGTGATCAGAAAA3′
siRNA silencing
The silencing reactions were carried out with siHERG
Silencer® pre-designed siRNA(Ambion#AM16708,Austin,
USA) against HERG1 with the following sequences: sense,
GAUAGGCAAACCCUACAACtt; antisense, GUU
GUAGGGUUUGCCUAUCtg.
In addition, we used a siRNA expression vector,
pSilencer 2.0-U6, which includes a RNA polymerase III
promoter (U6, Ambion) to drive expression of a short
hairpin RNA that mimics the structure of a siRNA (shRNA-
U6) [46]. Transfection was performed with a mix of two
constructs, one against nucleotide sequence 2697–2715, the
other one against nucleotide sequence 3182–3200 of r-
ERG1. For transfection reactions, 60–190 nM of siHERG
in the total culture volume was used. Negative controls
were transfection reactions without siRNA or with the non-
specific BLOCK-iT™ fluorescent oligo (Invitrogen) with
the end concentration of 40–75 nM in the total cell culture
volume. Transfection was carried out with Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. In brief, SCLC cells were plated in culture medium in
96-well plates 24 h before transfection. The si(HERG)
Silencer® pre-designed siRNA, pSilencer 2.0-U6, or
BlockiT™ were diluted with opti-MEM and incubated for
5 min. In a second tube, Lipofectamine 2000 was diluted
with opti-MEM and also incubated for 5 min. Both
dilutions were combined and incubated for another
20 min before adding to the SCLC cells. For the
proliferation studies, 6.4×10
3 cells in 80 μl culture medium
per 96 microtiter well were used, and for the transfection
reaction for Western blot analysis 3.0×10
5 cells in 6 ml
culture medium in 50-ml flasks (24 cm
2).
For electrophysiological recordings, SW2 cells were
plated in 35 mm Nunc dishes coated with poly-D-lysine
and transfected as described above using siRNA at end
concentrations of 40 nM for BLOCK-iT and 60 nM for
siHERG. In these experiments, cells were co-transfected
with cDNA encoding EGFP-N1 (subcloned in pcDNA3;
0.8 ng/μl; Clontech) to identify successfully transfected
cells.
Western blotting
To obtain cell lysate, SW2 cells were washed with cold
phosphate-bufferedsaline,collectedandhomogenizedinlysis
buffer (25 mM Tris–HCl, 250 mM sucrose, 20 mM EDTA;
protease inhibitors: 2 μgm l
−1 leupeptin, aprotinin, and
pepstatin A (Sigma); 0.1 mM phenylmethylsulfonyl fluoride
(Sigma), 2 mM Na3O4V (Merck-Calbiochem), pH 7.2) and
incubated on ice for 10 min. The lysate was centrifuged for
5 min at 800 g, and the cell debris was removed. For
immunoblotting, the ERG1 antibody (Chemicon) targeted
against the C terminus of the human correlate of ERG1,
HERG1 (aa 1145–1159) [33] was used with the ECL Plus
Western Blotting Detection System (Amersham). The anti-
body against β-actin was purchased from Sigma.
Results
HERG currents in SW2 cells
Membrane currents were recorded in SW2 cells by using
experimental conditions and pulse protocols optimized to
Pflugers Arch - Eur J Physiol (2012) 463:365–376 367detect native ERG K
+ currents [6, 20]. The external K
+
concentration was increased to 40 mM, since in addition to
an increase of the driving force for K
+ at negative membrane
potentials the ERG channel conductance is larger in an
elevated external K
+ concentration [41, 45]. The holding
potential was shifted to a depolarized potential (−20 mV) to
maximally activate HERG channels. The transient and part
of the steady-state currents of the membrane currents shown
in Fig. 1a were blocked by 10 μM E-4031 (Fig. 1b), a
specific HERG channel blocker [44, 52]. HERG currents
were isolated as E-4031-sensitive currents (Fig. 1c)b y
subtracting membrane currents recorded in the presence of
E-4031 from control currents [7, 38]. The current-potential
relation was constructed by plotting the amplitudes of the
transient and steady-state HERG currents against test
potential. At potentials more positive than −40 mV, HERG
currents had tiny current amplitudes, whereas at potentials
more negative than −40 mV transient inward currents
occurred. Their amplitudes increased with more negative
potentials demonstrating the strong inwardly rectifying
properties of the HERG current (Fig.1d). These transient
currents as well as the tail currents recorded with the
constant −100 mV pulse exhibited the characteristic
“hook”-like shape caused by fast recovery from HERG
channel inactivation and subsequent slow deactivation. The
tail current amplitudes increased with more positive prepulses
until a constant current amplitude was reached at prepulses
more positive than −30 mV. HERG currents were recorded in
SW2 cells as well as in the three other SCLC cell lines
investigated (OH1, OH3, H82; see Table 1). HERG current
properties of OH1, OH3, and H82 cells were similar to those
of SW2 cells (data not shown). Since the percentage of cells
containing HERG currents was higher in SW2 cells (88%)
than in the other cell lines (Table 1), this study focused on
SW2 cells. However, some of the crucial experiments were
also done on OH1, OH3, and H82 cells to test whether the
results obtained in SW2 cells were similar in the four SCLC
cell lines.
The resting potential of SW2 cells varied between −40
and −59 mV (−47±2 mV; n=8) and was depolarized by 13±
2 mVafter application of 1 μM E-4031. Upon wash-out, no
recovery was observed within 3 min (Fig. 2a) in accordance
with previous observations [52]. To determine the degree of
HERG channel activation near the resting potential, peak tail
current amplitudes elicited with the activation protocol (see
legend of Fig. 2) were measured. As in the current clamp
experiments, the external solution was Ringer’s solution.
From the activation curve (Fig. 2c), it can be seen that, at the
resting potential of SW2 cells of about −45 mV, a fraction of
HERG channel conductance was already activated, explain-
ing its contribution to the maintenance of the resting
potential.
No effect of HERG channel blockage by E-4031 on cell
proliferation
To study the effect of HERG channel blockage by E-4031
on SW2 cell proliferation, SW2 cells were incubated with 1
or 5 μM E-4031 for 24, 48, or 72 h in the culture medium.
As shown in Fig. 3 and Table 1, there was no statistically
significant change in the proliferation of SW2 cells as
compared with the controls. Since there was a tendency to
smaller values of cell proliferation after 72 h E-4031
incubation, we performed an additional experiment in
which SW2 cells were incubated with E-4031 for 72 h.
As compared with the controls (n=21) incubation with
1 μM E-4031 yielded a normalized value of cell proliferation
of 1.07 (n=12) and with5 μM E-4031 of 1.08 (n=12).Both
differences were statistically not significant. Cell prolifera-
tion was also not reduced by E-4031 in the other SCLC cell
lines (OH1, OH3, H82; Table 1). This result was astonishing,
Fig. 1 ERG currents in SW2 cells. Membrane currents of a SW2 cell
recorded in a solution containing 40 mM K
+ under control conditions
(a) and in the presence of 10 μM E-4031 (b). From a holding potential
of −20 mV a 2-s depolarizing prepulse to 20 mV was followed by a
0.5-s gap and 1-s test pulses to potentials between 40 and −120 mV in
10-mV increments. During a final 200 ms pulse to −100 mV tail
currents were recorded (see pulse diagram). c E-4031-sensitive
currents, obtained by subtracting the membrane currents shown in b
from the control currents in a. Symbols denote where peak inward and
outward currents (filled diamond) and steady-state currents (open
diamond) were determined. d Current–potential curves, amplitudes of
peak and steady-state currents of the E-4031-sensitive currents (c)
were plotted versus test pulse potential. Data points were connected by
continuous lines
368 Pflugers Arch - Eur J Physiol (2012) 463:365–376since HERG channel-containing tumor cells so far investi-
gated were sensitive to pharmacological HERG channel
blockage [5, 29, 55].
To test whether E-4031 was still effective after an
incubation time of 72 h, a solution of 5 μM E-4031 in
culture medium was stored in the incubator for 72 h. From
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Fig. 2 E-4031 depolarizes the resting potential.aRecording of
resting potential in a SW2 cell. Application of 3 μM E-4031 induced a
depolarization which was not reversible within the recording time. b
Superimposed tail current recordings elicited with a pulse to −100 mV,
preceded by 4-s test pulses to potentials between 20 and −80 mV from
a holding potential of −80 mV. Extracellular solution: Ringer’s with
5m MK
+. c Activation curve. Tail current amplitudes as shown in b
were normalized (n=6), averaged,plottedversustheprecedingtestpulse
potential and fitted with a Boltzmann function, yielding V0.5=−18.5 mV
and k=11.9 mV
Fig. 3 No influence of ERG channel blockage by E-4031 on SW2
cell proliferation. SW2 cells were incubated without (control) and with
E-4031 (1 and 5 μM) for 24, 48, and 72 h. As compared with controls,
no significant change in cell proliferation was detected. Cell
proliferation was normalized to control values
Pflugers Arch - Eur J Physiol (2012) 463:365–376 369this solution, a 100 nM E-4031 solution was prepared using
an extracellular solution containing 40 mM KCl. We used
100 nM E-4031, since this is the lowest concentration
which fully blocks ERG channels in GH3 cells [52]. This
concentration blocked HERG currents in four of four SW2
cells (Fig. 4a) demonstrating that E-4031 was not
degraded or metabolized after 72 h in culture medium
at 37°C. To exclude the possibility that such a large
percentage of E-4031 was bound to the proteins of the
culture medium [25, 51] that the free E-4031 concentra-
tion was insufficient to produce an effective block of ERG
channels during the incubation period, we perfused SW2
cellswithculturemediumcontaining1μME-4031whichhad
been incubated for 72 h in the presence of SW2 cells. As
shown in Fig. 4b, the HERG current was totally blocked
under these conditions (n=5). Since about 70% of E-4031 is
bound to the protein in the culture medium [51], the
remaining 30% of “free” E-4031 is sufficient to induce a
full blockage of HERG channels. Perfusion of SW2 cells
with preincubated culture medium in the absence of E-4031
showed no significant decrease of the transient peak HERG
current amplitude, measured at −120 mV (107.0±5.0% of
the control current amplitude measured in Ringer’ss o l u t i o n ;
n=4).
The E-4031-induced depolarization of the resting poten-
tial was discussed as one explanation for the reduction of
cell proliferation in other tumors [28, 47]. To exclude the
possibility that during sustained application of E-4031 the
initial depolarization was removed or compensated for, we
measured the resting potential in SW2 cells after the
continued presence of E-4031 for 24 and 72 h. After 24 h
in culture with 5 μM E-4031, SW2 cells were depolarized
(−36±3 mV; n=11) as compared with control cells without
E-4031 (−48±3 mV; n=7; p=0.016). SW2 cells incubated
with 5 μM E-4031 for 72 h were also depolarized (−29±
4m V ;n=9) as compared with control cells (−50±1 mV; n=
12; p<0.001). Fig. 5a shows an example of the recording of
the resting potential in an untreated control cell and in a cell
which had been incubated together with 5 μM E-4031 for
72 h. In subsequent voltage clamp recordings, typical
HERG currents were visible in all control cells (Fig. 5b),
despite the small HERG channel conductance in Ringer’s
solution. In contrast, HERG current was absent in the SW2
cells pretreated with E-4031. From these experiments, it
Fig. 4 E-4031 remains effective after 3 days in culture. a Membrane
currents recorded with 500-ms test pulses using the pulse protocol
shown in Fig. 1 before (control) and after application of 100 nM E-
4031. External solution contained 40 mM K
+. The E-4031 solution
was prepared from an E-4031 stock solution incubated for 3 days at
37°C in the culture medium. b Membrane currents recorded in
Ringer’s solution containing 5 mM K
+ and after perfusion of SW2
cells with preincubated culture medium containing 1 μM E-4031. The
same pulse protocol was used as shown in Fig. 1 (illustrated current
traces were obtained with test pulse potentials between −20 and
−120 mV in steps of −10 mV)
Fig. 5 SW2 cells incubated with E-4031 for 3 days remain
depolarized. a Resting potential of a control SW2 cell (control) and
a SW2 cell which had been staying in culture in the presence of 5 μM
E-4031 for 72 h (E-4031). The Ringer’s solution in which cells which
had been incubated with E-4031 were recorded contained 2% of the
72 h preincubated 5 μM E-4031 culture medium. b, c Membrane
currents of the control cell (b) and the cell preincubated with 5 μME -
4031 (c) shown in a were recorded with the pulse protocol illustrated
in Fig. 1 (test pulse duration 500 ms). Tail current recordings zoomed
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remained depolarized for at least 72 h in the presence of E-
4031 and that this sustained depolarization did not affect
cell proliferation. However, since the resting potential of
tumor cells containing ERG channels varies with the stage
of the cell cycle, part of the differences in the resting
potential in the presence and absence of E-4031 could be
due to the fact that SW2 cells were not synchronized in a
certain stage of the cell cycle [4].
Inhibition of HERG1 protein expression by siRNA reduced
cell proliferation
To study whether inhibition of HERG channel protein
expression would reduce SW2 cell proliferation, we first
determined which members of the HERG channel family
were expressed in SCLC cells. Using RT-PCR, we found
transcripts of the two splice variants HERG1a and
HERG1b. In addition, HERG2 and HERG3 were detected
in SW2 cells and in the three other SCLC cell lines (OH1,
OH3, H82; Fig. 6a–c). To inhibit HERG1 expression, SW2
cells were transfected with siRNA with sequences of sense
and antisense directed against both ERG1 isoforms (see
“Methods”). This treatment abolished HERG current
(Fig. 7c) whereas HERG currents were still recorded in
SW2 cells transfected with EGFP alone (Fig. 7a; control) or
together with siBlockiT (Fig. 7b). In four out of five SW2
cells transfected with siHERG and EGFP, no HERG current
was recorded, in one SW2 cell a small amplitude HERG
current was present (4.2 pA/pF; Fig.7d). HERG current
density (pA/pF) of EGFP-expressing cells measured 48 to
58 h after transfection (pulse protocol as in Fig. 1) was 13.7
±8.5 pA/pF (n=5) and 18.2±8.1 pA/pF (n=5) in cells
transfected with siBlockiT. This result indicated that siRNA
against ERG1 was very effective in cells successfully
transfected. Since transfection with siRNA against ERG1
almost abolished HERG current, we assumed that HERG
current in SW2 cells was predominantly mediated by
HERG1. We therefore did not investigate the effect of
siRNA against ERG2 and ERG3.
To investigate whether siRNA against ERG1 would
decrease cell proliferation, SW2 cells were transfected with
siRNA against ERG1 (siHERG1). Cell proliferation was
significantly reduced by about 40% after 72 h and by about
60% after 96 h after siRNA transfection as compared with
control cells (Fig. 8a; Table 2). Control cells were incubated
with Lipofectamine alone or transfected with the nonspecific
siBlockiT. In the same experiment, i.e., using the same
controls, cell growth was reduced to a similar degree as with
siHERG1 by inhibition of HERG channel protein expression
with the short hairpin RNA against ERG1 (shRNA-U6)
(Fig. 8a). No change in cell growth was observed after
transfection with siBLOCKiT (Table 2). In two independent
additional experiments using the same experimental design,
the inhibiting effect of siRNA and shRNA-U6 on cell growth
was confirmed (Table 2). The reduction of HERG1 protein
content by siRNA was verified by Western blotting of SW2
cells after incubation for 48 and 72 h (Fig. 8b). The two
photomicrographs (Fig. 8c “a” and “b”) show the decrease in
SW2 cell growth and density in the presence of siHERG. In
another set of experiments, we compared the effect of siRNA
against ERG1 in SW2 cells with that in the other three cell
lines. In all SCLC cell lines investigated, cell proliferation
was significantly reduced by siRNA against ERG1 (Table 3).
Whereas transfection of SW2, OH1, and H82 cells with
siBlockiT yielded no significant change in cell growth,
transfection of OH3 cells with siBlockiT significantly
reduced cell proliferation. However, the decrease in
siHERG1-induced cell proliferation was still significantly
larger than that induced by siBlockiT (p<0.001). Since the
transfection rate was not 100%, we assume that the reduction
in HERG protein content and reduction of cell proliferation
would be larger if the transfection would be more efficient.
Fig. 6 SW2 cells express multiple ERG subunits. Using RT-PCR,
mRNA transcripts for HERG1a and HERG1b (a) and for HERG1,
HERG2, and HERG3 were detected in four SCLC cell lines (SW2,
OH1, OH3, H82) (b, c)
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We found that, in SW2 cells as well as in three other SCLC
cell lines (OH1, OH3, H82), HERG1 channels are
expressed and that HERG2 and HERG3 transcripts were
also present. Selective pharmacological blockage of HERG
currents with E-4031 did not influence SCLC cell prolifer-
ation. However, siRNA inhibition of HERG1 protein
expression almost abolished HERG currents and strongly
reduced SCLC cell proliferation. These results suggest that
HERG currents in these tumor cells are predominantly
mediated by HERG1 channels and that the presence of
HERG1 channel protein is important for cell growth,
whereas the conductive function of HERG channels does
not influence cell proliferation of SCLC cells.
Pharmacological blockage of Kv channels and cell growth
So far, the main emphasis in the discussion about the
oncogenic potential of ERG K
+ channels was concentrated
on the observation that pharmacological blockage of K
+
channels reduced cell growth. In 1996, Wonderlin and Strobl
[54] reported that pharmacological blockage of K
+ channels
with tetraethylammonium-chloride (TEA), quinidine, or 4-
aminopyridine (4-AP) reduces cell proliferation in healthy
cells (lymphocytes and Schwann cells) as well as in tumor
cells (melanoma and breast cancer cells). Since their review,
the list of normal tissue, tumor cell lines, and primary tumors
which show reduced cell growth upon pharmacological
blockage of K
+ channels has grown [5, 28, 47, 55].
However, the mechanisms underlying the inhibitory effects
of pharmacologically blocked K
+ channels on cell growth,
migration, or invasiveness remain still elusive. Several
hypotheses have been discussed. First, it had been argued
that the depolarization induced by K
+ channel block or K
+
channel activity itself could be important, either because of
the ion flux through the channel pore or due to the
accompanying local changes in the K
+ concentration.
Second, it was assumed that movements of parts of the K
+
channel protein during gating could influence neighboring
scaffold proteins or proteins involved in the cell cycle [18].
Previously, it has been shown that, even in some SCLC cell
lines (H69, H128, H146) different from those studied in this
project, incubation with TEA or 4-AP inhibited cell growth.
Since both substances are affecting a broad band of K
+
Fig. 7 Inhibition of HERG currents in SW2 cells transfected with
siRNA against ERG1. Membrane currents recorded from a SW2 cell
transfected with EGFP alone (control) (a), and from SW2 cells
transfected with siBlockiT (b) or siHERG1 (c). d Mean ERG current
density measured in control cells and in cells treated with siBlockiT or
siRNA against ERG1 (siHERG1). Five cells in each group
Fig. 8 Inhibition of HERG channel protein expression decreases cell
proliferation. a Data from SW2 cells transfected with siHERG for 72 h
(dark columns) and 96 h (white columns). Control cells were treated
with Lipofectamine and Opti-MEM only or transfected with
siBlockiT. Cell proliferation was inhibited following transfection with
siRNA against ERG1 (siHERG) and shRNA-U6 against ERG1 (U6).
Cell proliferation was normalized to control values. For quantitative
details, see Table 2. b Western blot of HERG1 protein levels in SW2
cells treated with siHERG and siBlockiT for 48 and 72 h, respectively.
β-actin was used as a loading control. c Photomicrographs of SW2
cells grown in control medium or in the presence of siHERG1 for
72 h. Scale bars, 500 μm
372 Pflugers Arch - Eur J Physiol (2012) 463:365–376channels including ERG channels [35, 48], it is not clear
which type of K
+ channel is responsible for this inhibition
[26, 27].
ERG channels and cell growth
As compared with normal tissue, ERG K
+ channels are either
overexpressed or newly expressed in primary tumors of
various histogenesis [11, 34]. Selective pharmacological
blockage of ERG channels reduced cell proliferation and
tumor invasiveness in almost all tumor cells so far
investigated, e.g., in hematopoetic malignancies [31, 43],
colorectal carcinomas [16], and melanoma cells [1]. The
function of HERG channels in tumor cells was thought to
contribute to the maintenance of a more depolarized
membrane potential, thereby permitting an easier passage
through the cell cycle, since depolarization is needed for cell
cycle progression [29]. In human primary acute myeloid
leukemia, the amount of expression of the two isoforms
HERG1a and HERG1b is strongly cell cycle-dependent,
with HERG1a predominantly expressed during the G1 phase
and HERG1b in the S phase, thereby influencing the relative
amount of HERG channel heteromers or homomers [14].
Since in SCLC cells, at least four HERG subunits are
expressed (HERG1a, HERG1b, HERG2, and HERG3), they
could form heteromeric channels [53]. This heteromeric
channel formation is also possible for human prolactinoma
cells [9]. However, we do not know to which degree
heteromeric HERG channels are formed and whether all or
only HERG1 channel subunits support cell proliferation. So
far, the literature has been dealing predominantly with
HERG1 and its two main isoforms. Our present data support
the importance of HERG1 in SCLC cells, especially our
result that siRNA against HERG1, i.e., the two isoforms of
HERG1, strongly reduced HERG current, although tran-
scripts of HERG2 and HERG3 subunits were also expressed.
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Table 3 Inhibition of HERG1 channel protein expression reduces cell
proliferation in SCLC cells
Cell line Control siBlockiT siHERG1
SW2 1.00±0.06 0.97±0.05 0.42±0.06***
OH1 1.00±0.08 0.84±0.08 0.73±0.07*
OH3 1.00±0.09 0.49±0.03*** 0.21±0.03***
H82 1.00±0.06 0.82±0.05 0.36±0.03***
Cell proliferation measured in four SCLC cell lines (SW2, OH1, OH3,
H82) after incubation with Lipofectamine alone (control), siBlockiT,
and siRNA against ERG1 (siHERG1) for 96 h (mean ± SEM). Each
mean value was calculated from 12 measurements and normalized to
the mean value of the corresponding control. The level of statistical
significance as compared with the controls was calculated by using the
t-test with Bonferroni correction
*p<0.05, **p<0.01, ***p<0.001 are the levels of significance
Pflugers Arch - Eur J Physiol (2012) 463:365–376 373It is still a mystery which role ERG channels play in the
malignant transformation from a normal cell to a tumor cell
and which functional role they play for tumor growth,
invasiveness, and formation of metastases. In melanoma
and SH-SY5Y neuroblastoma cells, proliferation and
migration of cells are attenuated by both, pharmacological
HERG channel blockage with E-4031 and siRNA-induced
inhibition of HERG protein expression [1, 57]. In contrast,
our data show that pharmacological blockage of HERG
channels in four defined SCLC cell lines does not influence
cell proliferation, whereas cell proliferation is reduced by a
decrease in the cellular content of the HERG channel
protein. Since not all SCLC cells were transfected with
siRNA against HERG1, the decrease of HERG channel
protein and probably the ensuing degree of cell growth
reduction would have been larger with a higher transfection
rate. Probably, the transfection rate could be increased by
using viral transduction [2]. We did not analyze the
function of the HERG protein in the cellular processes
underlying cell growth. It could be possible that the HERG
channel protein is necessary for cell cycle regulation [39].
ERG channel proteins have also been shown to interact
with integrins, thereby regulating cell survival and migra-
tion [3]. In neuroblastoma cells, ERG channels are
activated upon integrin-mediated adhesion of the cells to
extracellular matrix molecules like fibronectin and vitro-
nectin [21]. This important functional linkage between
ERG channels and integrins may explain the involvement
of ERG channels in cell migration. Other proteins presum-
ably involved in mitogenesis have been reported to bind to
HERG1 channels, like the adaptor protein 14-3-3 [22], Src
tyrosine kinase [12], or the TNF-α receptor [49]. Prelim-
inary experiments in our laboratory have shown that there is
also a linkage between the cell adhesion molecule NCAM
and HERG1 in SW2 cells (unpublished data by Kleene,
Schumacher, Schwarz).
HERG channel blockers have been used to reduce cell
growth in some types of tumors [5, 40, 55]. From our
experiments, it can be inferred that pharmacological blockage
of HERG channels is not a therapeutically useful approach in
SCLC cancer. A starting point for considering a potential
therapeutic strategy in SCLC cancer could be the inhibition of
cell proliferation by siRNA. Indeed, in vivo experiments have
recently shown that injection of siRNA against HERG1 into
SH-SY5Y tumors which had been inoculated subcutaneously
in nude mice inhibited tumor growth [57]. Another yet
relatively unexplored field is the use of HERG channel
proteins as specific tumor markers [16].
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